Information Provided By: 
Fly News Breaks for June 8, 2016
BAX, NXTM
Jun 8, 2016 | 06:03 EDT
Piper Jaffray analyst Matt O'Brien views Baxter's (BAX) decision to cancel its efforts for home hemodialysis as a net positive for NxStage Medical (NXTM). The news highlights the high bar to enter the category, one that NxStage has largely overcome, O'Brien tells investors in a research note. Further, there is now one less potential competitor in the space, the analyst contends. He keeps an Overweight rating on NxStage with a $21 price target.
News For NXTM;BAX From the Last 2 Days
